C. Pelligra

Thermo Fisher Scientific (United States)

Economics, Econometrics and FinanceMedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “1314P Patient-reported outcomes (PROs) from the phase III EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel (doc) in metastatic non-small cell lung cancer (mNSCLC)”.

1314P Patient-reported outcomes (PROs) from the phase III EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel (doc) in metastatic non-small cell lung cancer (mNSCLC)

Annals of Oncology(2024)10.1016/j.annonc.2024.08.1371

N/A

0DataRank · unranked

2 citations

Luis Paz‐Ares, M.C. Garassino, Shobhit Baijal, J. Bennouna, D.B. Daniel +12 more